CARE Checklist — Completed Against Manuscript

Manuscript: “Preoperative Embolisation of Sclerosing Stromal Tumor Associated with Good Clinical Outcome: A Case Report”

Topic	Item	Checklist item description	Reported on Line
Title	1	The diagnosis or intervention of primary focus followed by the words “case report”.	Lines 2–3
Key Words	2	2 to 5 key words identifying diagnoses/interventions, including “case report”.	Lines 51–52 (keywords listed; “case report” is not included)
Abstract	3a	Introduction: what is unique and what it adds to the literature.	Lines 21–26, 44–50
Abstract	3b	Main symptoms and/or important clinical findings.	Lines 27–43
Abstract	3c	Main diagnoses, therapeutic interventions, and outcomes.	Lines 27–43
Abstract	3d	Conclusion / main take-away lesson.	Lines 44–50
Introduction	4	One or two paragraphs summarizing why the case is unique.	Lines 56–74
Patient Information	5a	De-identified patient-specific information.	Lines 76–88
Patient Information	5b	Primary concerns and symptoms.	Lines 78–86
Patient Information	5c	Medical, family, and psychosocial history, including relevant genetic information.	Lines 79–82 (medical history; family, psychosocial, and genetic history not reported)
Patient Information	5d	Relevant past interventions with outcomes.	Lines 81–82 (antibiotic treatment for presumed UTI; outcome not specified)
Clinical Findings	6	Significant physical examination and clinical findings.	Lines 85–88
Timeline	7	Historical and current information organized as a timeline.	Not reported (no timeline format or dated sequence provided)
Diagnostic Assessment	8a	Diagnostic testing (physical examination, labs, imaging, etc.).	Lines 87–88, 93–138
Diagnostic Assessment	8b	Diagnostic challenges.	Lines 76–82, 139–146, 227–230
Diagnostic Assessment	8c	Diagnosis, including other diagnoses considered.	Lines 139–146, 190–193
Diagnostic Assessment	8d	Prognosis (e.g., staging in oncology), where applicable.	N/A (benign ovarian SST; staging not applicable in this case report)
Therapeutic Intervention	9a	Types of therapeutic intervention.	Lines 149–157, 165–183
Therapeutic Intervention	9b	Administration of intervention (dose, strength, duration, etc.).	Lines 154–157 (NBCA embolization); Lines 172–183 (operative details). Dose/duration not reported where applicable.
Therapeutic Intervention	9c	Changes in intervention, with rationale.	Lines 144–155, 165–183 (embolization followed by surgery; rationale stated)
Follow-up and Outcomes	10a	Clinician- and patient-assessed outcomes, if available.	Lines 195–201 (clinical outcome; patient-assessed outcome not reported)
Follow-up and Outcomes	10b	Important follow-up diagnostic and other test results.	Lines 191–193, 199–201 (histopathology; surveillance planned, subsequent results not reported)
Follow-up and Outcomes	10c	Intervention adherence and tolerability; how assessed.	Not reported
Follow-up and Outcomes	10d	Adverse and unanticipated events.	Lines 183, 195–198 (no reported complications/significant bleeding; no transfusion)
Discussion	11a	Scientific discussion of strengths and limitations.	Lines 245–250, 267–274

Topic	Item	Checklist item description	Reported on Line
Discussion	11b	Discussion of relevant medical literature with references.	Lines 203–266
Discussion	11c	Scientific rationale for conclusions, including possible causes.	Lines 231–250, 257–266
Discussion	11d	Primary take-away lessons in a one-paragraph conclusion.	Lines 275–284
Patient Perspective	12	Patient perspective in one to two paragraphs on treatment(s).	Lines 296–298 (parent perspective only; patient perspective not provided)
Informed Consent	13	Whether informed consent was given; provide if requested.	Lines 301–303 (written parental consent reported)

Note: Line references are based on the manuscript's supplied line numbering. Items identified as not reported indicate information absent from the manuscript; they should not be treated as N/A unless the authors confirm that the criterion does not apply.